4,7-Dihydro-5-methyl-7-(1-methylethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic Acid 1,1-dimethylethyl Ester → 1-[(4,7-Dihydro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)carbonyl]-4-phenylpiperazine
Reaction equation
N[C:2]1[CH:6]=[CH:5][NH:4]N=1.CC(O[C:12]([C:14]1[CH:19](C(C)C)[N:18]2[N:23]=[CH:24][CH:25]=[C:17]2[NH:16][C:15]=1[CH3:26])=[O:13])(C)C>>[CH3:26][C:15]1[NH:16][C:17]2[N:18]([N:23]=[CH:24][CH:25]=2)[CH2:19][C:14]=1[C:12]([N:16]1[CH2:17][CH2:25][N:4]([C:5]2[CH:6]=[CH:2][CH:19]=[CH:14][CH:12]=2)[CH2:26][CH2:15]1)=[O:13]Participants
3
Procedure
Condensation of compound 3 and compound 4 as described in Example 18, Method 2 Step C provided the title compound. Reverse Phase LC/MS: YMC S5 ODS 4.6×50 mm Ballistic column, UV detection at 220λ, 4 min. gradient 0-100% Solvent B/A (Solvent A: 10% MeOH/H2O with 0.1% TFA, Solvent B: 90% MeOH/H2O with 0.1% TFA), 4 mL/min. Rt=1.96 min, (87% pure). (M+H: 323).
Sources & evidence
- ORD record
- ord-597fe6403f9644519bd7f2c81d9ccbbb
- Source dataset
- uspto-grants-2004_03
- Patent number
- US06706720B2
Reaction notes
Loading…